The purpose of this study is to explore the possible association between the circadian disruption and cancer progression.
The biological markers that are assumed to bridge this association are measured and analyzed.
Study Type
OBSERVATIONAL
Enrollment
236
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Progression-free survival
The data progression-free survival will be done by reviewing patients' medical record.
Time frame: 3 years (and more) after recruitment
Circadian disruption
Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire will be used during assessment.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Objective sleep cycle measures
The assessment will be performed by using actigraph and sleep diary.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Physiological measures
The measures include blood pressure, body temperature, skin conductance, breathing pattern, and Electroencephalography.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Sleep quality measures
The measurements will be performed using Epworth sleepiness scale, Pittsburgh Sleep Quality Index, and Insomnia Severity Index.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Quality of Life measure
The measurement will be performed using M.D. Anderson Symptom Inventory.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Cancer related Fatigue
Fatigue severity scale will be used during the assessment.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Distress related measure
Hospital Anxiety and Depression Scale will be used during the assessment.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Posttraumatic Stress-related symptom measure
Impact of Event Scale-revised will be used to categorize and quantify Posttraumatic stress-related symptom in cancer patients.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Menopausal symptom measure
Menopause Rating Scale will be used during the assessment.
Time frame: Baseline, after 1 month, after 6 month, after 12 month
Personality measure
Temperament and Character Inventory will be used to examine the personality factor in each participant.
Time frame: Baseline
Genetic polymorphism
Variable Number Tandem Repeat and Single Nucleotide Polymorphism of circadian-rhythm related genes will be examined.
Time frame: Baseline
Epigenetic Change
The methylation specific Polymerase Chain Reaction technique will be used to explore methylation patterns in circadian clock gene or in a global gene level.
Time frame: Baseline
Cortisol level
Salivary cortisol level will be measured multiple times at baseline.
Time frame: Baseline
Melatonin
Salivary or Urine melatonin level will be measured.
Time frame: Baseline
Inflammatory markers
The various inflammation markers will be measured from blood sample.
Time frame: Baseline
Overall survival
The data progression-free survival will be done by reviewing patients' medical record.
Time frame: 3 years (and more) after recruitment